PANC Stock Overview
Panacos Pharmaceuticals, Inc., a development stage biotechnology company, engages in the discovery and development of small-molecule oral drugs designed to treat human immunodeficiency virus (HIV) and other human viral diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Panacos Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.0085 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 0% |
| 3 Year Change | -99.95% |
| 5 Year Change | 0% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| PANC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 1.5% | 1.2% |
| 1Y | 0% | 1.1% | 24.7% |
Return vs Industry: PANC exceeded the US Biotechs industry which returned -3.7% over the past year.
Return vs Market: PANC underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| PANC volatility | |
|---|---|
| PANC Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PANC's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine PANC's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | n/a | n/a | n/a |
Panacos Pharmaceuticals, Inc., a development stage biotechnology company, engages in the discovery and development of small-molecule oral drugs designed to treat human immunodeficiency virus (HIV) and other human viral diseases. The company’s discovery technologies focus on novel targets in the virus life cycle, including virus maturation and virus fusion. Its product pipeline includes second- and third-generation programs in HIV maturation inhibition.
Panacos Pharmaceuticals, Inc. Fundamentals Summary
| PANC fundamental statistics | |
|---|---|
| Market cap | US$53.00 |
| Earnings (TTM) | -US$35.75m |
| Revenue (TTM) | US$99.00k |
0.0x
P/S Ratio0.0x
P/E RatioIs PANC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PANC income statement (TTM) | |
|---|---|
| Revenue | US$99.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$99.00k |
| Other Expenses | US$35.85m |
| Earnings | -US$35.75m |
Last Reported Earnings
Sep 30, 2008
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did PANC perform over the long term?
See historical performance and comparison